menu
    • menu
    [{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"Capsule","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":1.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.25,"dosageForm":"Capsule","sponsorNew":"Revolution Medicines \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Royalty Pharma"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Daraxonrasib","moa":"||RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Revolution Medicines \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Summit Therapeutics"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.85999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0.75,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.85999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0.85999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.85999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Daraxonrasib

    Menu

    Daraxonrasib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib,Ivonescimab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Summit Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Revolution and Summit Collaborates to Evaluate RAS(ON) Inhibitors with Ivonescimab

                            Details : The collaboration aims to evaluate clinical-stage RAS(ON) inhibitors, including RMC-6236 (daraxonrasib), RMC-9805 (zoldonrasib) and RMC-6291 (elironrasib), in combination with ivonescimab.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 30, 2025

                            Lead Product(s) : Daraxonrasib,Ivonescimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Summit Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Royalty Pharma

                            Deal Size : $1,250.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Revolution Medicines Enters into $2 Billion Flexible Funding Agreement with Royalty Pharma

                            Details : The financing aims to advance the development and global commercialization of Revolution's leading RAS(ON) inhibitor portfolio, RMC-6236 (daraxonrasib), is being evaluated for RAS-mutated NSCLC.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 24, 2025

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Royalty Pharma

                            Deal Size : $1,250.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Revolution Medicines Doses First Patient in Phase 3 Trial of Daraxonrasib

                            Details : RMC-6236 (daraxonrasib) is an oral, direct RAS(ON) multi-selective inhibitor with the potential to help address a wide range of cancers driven by oncogenic RAS mutations.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 14, 2025

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC (RASolve 301)

                            Details : Daraxonrasib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2025

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $862.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Revolution Medicines Closes $750M Offering with Full Exercise of Additional Shares

                            Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 05, 2024

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $862.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $750.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Revolution Medicines Prices Upsized $750M Offering of Stock & Pre-Funded Warrants

                            Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $750.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $600.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Revolution Medicines Announces Commencement of Public Offering of Common Stock

                            Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 02, 2024

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $600.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Revolution Medicines Doses First Patient in Phase 3 Metastatic Pancreatic Trial

                            Details : RMC-6236 is a small molecule, RAS(ON) multi-selective inhibitor, given orally. It is being investigated for previously treated pancreatic ductal adenocarcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 21, 2024

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Aden...

                            Details : RMC-6236 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 03, 2024

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Revolution Medicines to Update RMC-6236 Pancreatic Cancer Program on July 15, 2024

                            Details : RMC-6236 is a small molecule, RAS(ON) multi-selective inhibitor, given orally. It is being investigated for the treatment of pancreatic ductal adenocarcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 08, 2024

                            Lead Product(s) : Daraxonrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth